Bhagwangar, D.K., Smith, M.R., & O’Rourke, J. S. ( 2008). Schering-Plough and concerns about Vytorin®. 08-11. Notre Dame, IN: The Eugene D. Fanning Center for Business Communication, Mendoza College of Business, University of Notre Dame.
Clinical tests showed cholesterol drug Vytorin® was not living up to the claims of the producers, Schering-Plough and Merck. Consumers could receive a virtually equivalent drug for one-third of the cost. The problem facing Schering-Plough was to find the best methods to reach its stakeholders and ensure them that their concerns will be addressed in a timely and effective manner. This case has health, financial, and legal ramifications for stakeholders.
You are not authorized to view Teaching Notes. Please contact your librarian for access or sign in to your existing instructor profile.